Skip to main content

Advertisement

Table 7 TEAEs by sex in the crossover phase while receiving LDX with an incidence of ≥10% in the dose-optimization and/or crossover phase

From: Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day

AE-Preferred Term Crossover Phase
  Males Females
  (n = 87) (n = 28)
  n (%) n (%)
Any AE 30 (34.5) 8 (28.6)
Abdominal pain upper 2 (2.3) 0 (0.0)
Affect lability 0 (0.0) 0 (0.0)
Decreased appetite 5 (5.7) 2 (7.1)
Headache 4 (4.6) 2 (7.1)
Insomnia 5 (5.7) 0 (0.0)
Irritability 1 (1.1) 0 (0.0)
Nausea 1 (1.1) 1 (3.6)